

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Oventus Medical Limited |
| ABN | 12 608 393 282 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------|
| Name of Director | Sue MacLeman |
| Date of last notice | 26 April 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Interests held by: Dalroar Pty Ltd (MacLeman Investment Trust) |
| Date of change | 29 June 2021 & 30 June 2021 |
| No. of securities held prior to change | Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust): 54,132 Ordinary Shares 50,000 Options at \$0.4228 ea, expiring 8 December 2024 988 Options at \$0.36 ea, expiring 30 June 2021 300,000 Options at \$0.40 ea, expiring 7 August 2025 |
| Class | Shares & Options |
| Number acquired | Indirect – Dalroar Pty Ltd (MacLeman Investment Trust) 83,330 Ordinary Shares & 41,665 Options exercisable at \$0.24 ea, expiring 29 June 2023 |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|---|
| Number disposed | Expired Options: Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust) 988 Options at \$0.36 ea, expiring 30 June 2021 |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$10,000 |
| No. of securities held after change | Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust): 137,462 Ordinary Shares 50,000 Options at \$0.4228 ea, expiring 8 December 2024 300,000 Options at \$0.40 ea, expiring 7 August 2025 41,665 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Participation in the Tranche 2 Placement approved by Shareholders on 21 June 2021 & Options expired on 30 June 2021 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | Nil |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|-----------------------|--|
| Interest after change | |
|-----------------------|--|

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Oventus Medical Limited |
| ABN | 12 608 393 282 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------------------|
| Name of Director | Christopher Patrick Hart |
| Date of last notice | 22 June 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Interests held by: C & L Super Pty Ltd as trustee for the Hart Superfund Larissa Diane Hart (spouse) as trustee for the Squirrel TST |
| Date of change | 29 June 2021 |

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| No. of securities held prior to change | <p>Direct: 500,000 Options at \$0.4228 ea, expiring 8 December 2024; 70,000 Options exercisable at \$1.0628 ea, expiring 8 December 2024; 5,000,000 Options exercisable at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect: Christopher Patrick Hart as trustee for the CHD (IP) Trust 26,334,847 Ordinary Shares & 104,167 Options exercisable at \$0.24 ea, expiring 21 June 2023</p> <p>Indirect: Interests held by C & L Super Pty Ltd as trustee for the Hart Superfund 40,000 Ordinary Shares</p> <p>Indirect: Larissa Diane Hart (spouse) as trustee for the Squirrel TST 376,000 Ordinary Shares</p> |
| Class | Shares & Options |
| Number acquired | Indirect: Christopher Patrick Hart as trustee for the CHD (IP) Trust 791,670 Ordinary Shares & 395,835 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Number disposed | N/A |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | \$95,000 |
| No. of securities held after change | <p>Direct: 500,000 Options at \$0.4228 ea, expiring 8 December 2024; 70,000 Options exercisable at \$1.0628 ea, expiring 8 December 2024; 5,000,000 Options exercisable at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect: Christopher Patrick Hart as trustee for the CHD (IP) Trust 27,126,517 Ordinary Shares & 104,167 Options exercisable at \$0.24 ea, expiring 21 June 2023 & 395,835 Options exercisable at \$0.24 ea, expiring 29 June 2023</p> <p>Indirect: Interests held by C & L Super Pty Ltd as trustee for the Hart Superfund 40,000 Ordinary Shares</p> <p>Indirect: Larissa Diane Hart (spouse) as</p> |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|--|---|
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Participation in the Tranche 2 Placement approved by Shareholders on 21 June 2021 |
|--|---|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | Nil |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Oventus Medical Limited |
| ABN | 12 608 393 282 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------------|
| Name of Director | Melvyn John Bridges |
| Date of last notice | 26 April 2021 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Adinbri Super Pty Ltd atf The Bridges Super Fund |
| Date of change | 29 June 2021 & 30 June 2021 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held prior to change | <p>Direct: 75,367 Ordinary Shares; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares & 58,674 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 474,276 Ordinary Shares, 3,295 Options at \$0.36 ea, expiring 30 June 2021, & 300,000 Options at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 820,939 Ordinary Shares & 6,591 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – Lucille Bridges (spouse) 158,203 Ordinary Shares & 9,887 Options at \$0.36 ea, expiring 30 June 2021</p> |
| Class | Shares & Options |
| Number acquired | Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 166,670 Ordinary Shares & 83,335 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Number disposed | <p>Expired Options:</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 58,674 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 3,295 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 6,591 Options at \$0.36 ea, expiring 30 June 2021</p> <p>Indirect – Lucille Bridges (spouse) 9,887 Options at \$0.36 ea, expiring 30 June 2021</p> |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$20,000 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| No. of securities held after change | <p>Direct: 75,367 Ordinary Shares; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024</p> <p>Indirect – interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares</p> <p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 474,276 Ordinary Shares & 300,000 Options at \$0.40 ea, expiring 7 August 2025</p> <p>Indirect – interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 987,609 Ordinary Shares & 83,335 Options exercisable at \$0.24 ea, expiring 29 June 2023</p> <p>Indirect – Lucille Bridges (spouse) 158,203 Ordinary Shares</p> |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Participation in the Tranche 2 Placement approved by Shareholders on 21 June 2021 & Options expired on 30 June 2021 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | Nil |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|-----------------------|--|
| Interest after change | |
|-----------------------|--|

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Oventus Medical Limited |
| ABN | 12 608 393 282 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|----------------|
| Name of Director | Paul Molloy |
| Date of last notice | 11 August 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 29 June 2021 & 30 June 2021 |
| No. of securities held prior to change | Direct: 104,167 Ordinary Shares, 52,083 Options at \$0.36 ea, expiring 30 June 2021 & 500,000 Options at \$0.40 ea, expiring 7 August 2025 |
| Class | Shares & Options |
| Number acquired | Direct – Direct – 416,670 Ordinary Shares & 208,335 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Number disposed | Expired Options: Direct: 52,083 Options at \$0.36 ea, expiring 30 June 2021 |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|---|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$50,000 |
| No. of securities held after change | Direct: 520,837 Ordinary Shares & 500,000 Options at \$0.40 ea, expiring 7 August 2025 208,335 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Participation in the Tranche 2 Placement approved by Shareholders on 21 June 2021 & Options expired on 30 June 2021 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | Nil |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| If prior written clearance was provided, on what date was this provided? | |
|--|--|

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Oventus Medical Limited |
| ABN | 12 608 393 282 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|----------------|
| Name of Director | Jake Nunn |
| Date of last notice | 11 August 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 29 June 2021 & 30 June 2021 |
| No. of securities held prior to change | Direct: 156,250 Ordinary Shares, 78,125 Options at \$0.36 ea, expiring 30 June 2021 & 500,000 Options at \$0.40 ea, expiring 7 August 2025 |
| Class | Shares & Options |
| Number acquired | Direct – 208,330 Ordinary Shares & 104,165 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Number disposed | Expired Options: Direct: 78,125 Options at \$0.36 ea, expiring 30 June 2021 |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|---|
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Nil |
| No. of securities held after change | Direct: 364,580 Ordinary Shares & 500,000 Options at \$0.40 ea, expiring 7 August 2025 104,165 Options exercisable at \$0.24 ea, expiring 29 June 2023 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Participation in the Tranche 2 Placement approved by Shareholders on 21 June 2021 & Options expired on 30 June 2021 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | Nil |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| If prior written clearance was provided, on what date was this provided? | |
|--|--|